Association of Apolipoprotein E Polymorphism with Lipoprotein Glomerulopathy

Yang, An Hang; Ng, Yee Yung; Tarng, Der‐Cherng; Chen, Jinn Yang; Shiao, Ming‐Shi; Kao, Jau-Tsuen

doi:10.1159/000044933

Cited by 16 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study of 57 non-insulin-dependent Japanese diabetic patients, Horita et al [33]found an increased frequency of apo ε2 allele among patients with renal failure. In another recent report from Taiwan, Yang et al [34]found 2 new cases of lipoprotein glomerulopathy, both exhibiting apo E3/E4 genotype. In a European study, Boize et al [35]reported a twofold increase of nephropathy in E2 non-carriers with non-insulin-dependent diabetes mellitus.…”

Section: Discussionmentioning

confidence: 99%

Increased Prevalence of Apolipoprotein E3/E4 Genotype among Swedish Renal Transplant Recipients

Roussos

Florén

Carlson

et al. 1999

Nephron

View full text Add to dashboard Cite

There is increasing evidence that lipoproteins are involved in the progression of kidney diseases and in the deterioration of kidney transplant function, although the exact mechanism is still not known. Common polymorphisms of apolipoprotein E genotype associate with the variability of lipoprotein levels and composition. We have, therefore, determined the apolipoprotein E genotype in a group of 112 renal transplant patients, of whom 27 had had an episode of acute vascular rejection, while 85 had not. We found no difference in apolipoprotein E genotype distribution or in relative allele frequency in the vascular rejection group as compared with the group without vascular rejection. The apolipoprotein E genotype distribution in the transplant group was also compared with that in a group of 407 healthy Swedish individuals. The E3/E4 genotype occurred with a significantly increased frequency in the transplant group: 38.3 versus 16% in the control group (p < 0.001). The prevalence of individuals carrying the Ε4 allele among the transplant group was also significantly higher (44%) as compared with the control group (30%; p < 0.01). This increase was entirely due to the predominant increase of E3/E4, as the E4/E4 genotype was less frequent in transplant recipients than in normal controls (3.5 vs. 10.6%; p < 0.05). The relative frequencies of Ε2 (0.044), Ε3 (0.716), and Ε4 (0.238) alleles in the renal transplant group were not different from those of normal controls (0.078, 0.718, and 0.202, respectively). With regard to the prevalence of E4/E4 in the two groups, the lack of difference in the relative frequency of the Ε4 allele must be interpreted with caution. The results thus suggest that the E3/E4 genotype may be associated with the progression of kidney disease leading to renal insufficiency. However, the apolipoprotein E genotype does not seem to influence the risk of vascular rejection among transplant recipients.

show abstract

Section: Discussionmentioning

confidence: 99%

Increased Prevalence of Apolipoprotein E3/E4 Genotype among Swedish Renal Transplant Recipients

Roussos

Florén

Carlson

et al. 1999

Nephron

View full text Add to dashboard Cite

show abstract

“…However, several new cases have recently been added to our file [9, 10, 11, 12, 13, 14]. To the best of our knowledge, 25 patients were reported from Japan, 1 from the United States [24], 2 from France [11, 25], 2 from Taiwan [12], and 2 from China [13, 14](fig. 5).…”

Section: Lipoprotein Glomerulopathymentioning

confidence: 99%

“…When the apo E phenotype was assayed by isoelectric focusing, most cases of LPG showed the heterozygous E2/3 or E2/4 [28], although a few were reported to have the wild-type E3/3 [25]or E2/2 that is found in familial type III hyperlipoproteinemia [33]. On the other hand, the apo E phenotype on a genetic basis (apo E genotype) determined by restriction fragment isotyping with Hha I was generally ε3/3 or ε3/4 [12, 15]. The discrepancy between the apo E phenotype and genotype indicates that the E2 isoform in LPG is not a product of the ordinary E2 gene in which codon 158 is different from that in the E3 gene [32].…”

Section: Apo E Variants and Polymorphismmentioning

confidence: 99%

“…In 1995, we reviewed this disease and reported both its histological characteristics and its lipid and lipoprotein profiles [7]. Since then, however, new cases and findings of LPG have been reported [8, 9, 10, 11, 12, 13, 14]. In particular, our project team has clarified that several novel apolipoprotein (apo) E variants are associated with LPG [15, 16, 17, 18].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Lipoprotein Glomerulopathy: Renal Lipidosis Induced by Novel Apolipoprotein E Variants

Saito¹,

Oikawa

Sato³

et al. 1999

Nephron

View full text Add to dashboard Cite

“…LPG recurs in transplanted kidneys (25)(26)(27), implicating systemic rather than renal factors in the development of the disease. Until now, a total of 34 cases of LPG have been reported, predominantly in Asians: 27 in Japanese (24,25,28 -33), 5 in Chinese (14,34,35), and 2 in French patients (36,37). At least 16 patients were heterozygous carriers of rare apoE variants.…”

Section: Discussionmentioning

confidence: 99%

Diminished LDL Receptor and High Heparin Binding of Apolipoprotein E2 Sendai Associated with Lipoprotein Glomerulopathy

Hoffmann

Scharnagl

Panagiotou

et al. 2001

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Abstract. Variants of apolipoprotein E (apoE) have been linked to lipoprotein glomerulopathy, a new glomerular disease characterized by the deposition of lipoproteins in mesangial capillaries. One third of affected patients are heterozygous for apoE2 Sendai (Arg145 Pro). Variants of apoE can also produce type III hyperlipoproteinemia (HLP). Recessive type III HLP is caused by apoE2 (Arg158 Cys), a mutant with diminished low-density lipoprotein (LDL) receptor binding but halfnormal heparin binding. Dominant type III HLP is caused by mutations that markedly alter heparin binding but modestly reduce receptor binding. This study examined whether apoE2 Sendai (Arg145 Pro) was functionally different from type III HLP-producing apoE variants by expressing apoE3, apoE2 (Arg158 Cys), apoE1 (Arg146 Glu), a dominant apoE variant, and apoE2 Sendai (Arg145 Pro) in the baculovirus system. LDL receptor binding was studied using recombinant apoE complexed to phospholipid vesicles and to very lowdensity lipoprotein from a patient with familiar apoE deficiency. Compared with apoE3, receptor-binding activities of apoE2 (Arg158 Cys), apoE1 (Arg146 Glu), and apoE2 Sendai (Arg145 Pro) all were less than 5%. Heparin-binding activities were 53%, 23%, and 66%, respectively, of apoE3. The distribution of apoE2 Sendai among the major plasma lipoprotein fractions was similar to that of apoE3 and apoE2 (Arg158 Cys). ApoE2 Sendai (Arg145 Pro) represents the only known mutation within the heparin-binding domain of apoE (residues 142 through 147), revealing diminished receptor binding and almost normal heparin binding. These unique characteristics of apoE2 Sendai (Arg145 Pro) may relate to the development of lipoprotein glomerulopathy.

show abstract

Association of Apolipoprotein E Polymorphism with Lipoprotein Glomerulopathy

Cited by 16 publications

References 12 publications

Increased Prevalence of Apolipoprotein E3/E4 Genotype among Swedish Renal Transplant Recipients

Increased Prevalence of Apolipoprotein E3/E4 Genotype among Swedish Renal Transplant Recipients

Lipoprotein Glomerulopathy: Renal Lipidosis Induced by Novel Apolipoprotein E Variants

Diminished LDL Receptor and High Heparin Binding of Apolipoprotein E2 Sendai Associated with Lipoprotein Glomerulopathy

Contact Info

Product

Resources

About